EyePoint Pharmaceuticals stock holds at USD 3.25 after loss

Published on 10/04/2026 at 13:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EyePoint Pharmaceuticals reported USD 507,000 in second-quarter revenue on September 28, 2026, down from USD 5.33 million. A 13-analyst consensus still rates the stock Buy.

EYPT, US30233B1098, Illustration mit AI erstellt.

EyePoint Pharmaceuticals (ISIN US30233B1098) closed at USD 3.25 on Nasdaq on October 2, 2026, after the company reported USD 507,000 in second-quarter revenue. The result keeps the clinical-stage biotech near the lower end of its USD 3.10 to USD 19.11 52-week range, while the next valuation test is tied to its late-stage eye-drug pipeline.

Revenue falls in second quarter

According to The Globe and Mail on September 28, 2026, revenue for the quarter ended June 30, 2026 was USD 507,000, compared with USD 5.33 million in the prior-year quarter. EyePoint also posted a GAAP net loss of USD 94.47 million, versus a GAAP net loss of USD 59.43 million a year earlier.

The comparison shows why revenue alone does not define the investment case. EyePoint is funding a clinical program centered on DURAVYU, an investigational sustained-delivery treatment for serious retinal diseases, so pipeline progress currently matters more than commercial sales.

Analysts see wide valuation gap

StockAnalysis reported on September 27, 2026 that 13 analysts held a consensus Buy rating, with an average 12-month price target of USD 25.91. The target lies 697.23 percent above the October 2 price of USD 3.25, while the published low and high targets were USD 4.00 and USD 68.00.

That spread reflects a binary development profile. A positive clinical readout could improve the commercial outlook, while the quarterly loss and the USD 94.47 million GAAP deficit underline the financing and execution risks attached to a clinical-stage business.

Nasdaq price stays near yearly low

EYPT traded within a USD 3.10 to USD 3.31 session range on October 2, 2026, opened at USD 3.31 and finished at USD 3.25, up USD 0.02 or 0.62 percent from the prior close of USD 3.23. Trading volume reached 3,103,882 shares, and the market capitalization was USD 272.5 million as of October 2, 2026.